Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome.

Banerjee A, Macdonald ML, Borgmann-Winter KE, Hahn CG.

Brain Res Bull. 2010 Sep 30;83(3-4):132-9. doi: 10.1016/j.brainresbull.2010.04.011. Epub 2010 Apr 28. Review.

2.

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.

Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ, Gallop RJ, Arnold SE.

Nat Med. 2006 Jul;12(7):824-8. Epub 2006 Jun 11.

PMID:
16767099
3.

Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Deng C, Pan B, Engel M, Huang XF.

Psychopharmacology (Berl). 2013 Mar;226(2):201-15. doi: 10.1007/s00213-013-3003-2. Epub 2013 Feb 7. Review.

PMID:
23389757
4.

Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life.

du Bois TM, Newell KA, Huang XF.

Eur Neuropsychopharmacol. 2012 May;22(5):356-63. doi: 10.1016/j.euroneuro.2011.09.002. Epub 2011 Oct 1.

PMID:
21962913
5.

Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.

Pitcher GM, Kalia LV, Ng D, Goodfellow NM, Yee KT, Lambe EK, Salter MW.

Nat Med. 2011 Apr;17(4):470-8. doi: 10.1038/nm.2315. Epub 2011 Mar 27.

6.

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, Rujescu D, Giegling I, Straub RE, McGee K, Gold B, Dean M, Muglia P, Callicott JH, Tan HY, Weinberger DR.

Arch Gen Psychiatry. 2010 Oct;67(10):991-1001. doi: 10.1001/archgenpsychiatry.2010.117.

7.

Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.

Buxbaum JD, Georgieva L, Young JJ, Plescia C, Kajiwara Y, Jiang Y, Moskvina V, Norton N, Peirce T, Williams H, Craddock NJ, Carroll L, Corfas G, Davis KL, Owen MJ, Harroch S, Sakurai T, O'Donovan MC.

Mol Psychiatry. 2008 Feb;13(2):162-72. Epub 2007 Apr 17.

8.

A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice.

Newell KA, Karl T, Huang XF.

Neuroscience. 2013 Sep 17;248:670-80. doi: 10.1016/j.neuroscience.2013.06.037. Epub 2013 Jun 27.

PMID:
23811072
9.

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.

Mei L, Xiong WC.

Nat Rev Neurosci. 2008 Jun;9(6):437-52. doi: 10.1038/nrn2392. Epub 2008 May 14. Review.

10.

Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.

Pan B, Huang XF, Deng C.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):924-30. doi: 10.1016/j.pnpbp.2011.04.002. Epub 2011 Apr 13. Review.

PMID:
21513767
11.

Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia.

Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, Williams HJ, Preece AC, Dwyer S, Wilkinson JC, Spurlock G, Kirov G, Buckland P, Waddington JL, Gill M, Corvin AP, Owen MJ, O'Donovan MC.

Am J Med Genet B Neuropsychiatr Genet. 2006 Jan 5;141B(1):96-101.

PMID:
16249994
12.

Schizophrenia: more evidence for less glutamate.

Morrison PD, Pilowsky LS.

Expert Rev Neurother. 2007 Jan;7(1):29-31.

PMID:
17187494
13.

Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.

Geddes AE, Huang XF, Newell KA.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):896-904. doi: 10.1016/j.pnpbp.2011.02.017. Epub 2011 Mar 1. Review.

PMID:
21371516
14.
15.

The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons.

Allison JG, Das PM, Ma J, Inglis FM, Jones FE.

Neurosci Res. 2011 Jun;70(2):155-63. doi: 10.1016/j.neures.2011.02.009. Epub 2011 Feb 23.

PMID:
21352860
16.

Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model.

Papaleo F, Yang F, Paterson C, Palumbo S, Carr GV, Wang Y, Floyd K, Huang W, Thomas CJ, Chen J, Weinberger DR, Law AJ.

J Neurosci. 2016 Apr 27;36(17):4859-75. doi: 10.1523/JNEUROSCI.4632-15.2016.

17.

Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.

Bennett M.

Aust N Z J Psychiatry. 2009 Aug;43(8):711-21. doi: 10.1080/00048670903001943. Review.

PMID:
19629792
18.

Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.

Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W, Thomas CJ, Vakkalanka R, Besterman AD, Lipska BK, Hyde TM, Harrison PJ, Kleinman JE, Weinberger DR.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12165-70. doi: 10.1073/pnas.1206118109. Epub 2012 Jun 11.

19.

Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia.

Agim ZS, Esendal M, Briollais L, Uyan O, Meschian M, Martinez LA, Ding Y, Basak AN, Ozcelik H.

PLoS One. 2013;8(1):e53042. doi: 10.1371/journal.pone.0053042. Epub 2013 Jan 3.

20.

Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice.

Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson H, Sigmundsson A, Firth DR, Nielsen B, Stefansdottir R, Novak TJ, Stefansson K, Gurney ME, Andresson T.

J Neurosci. 2007 Apr 25;27(17):4519-29.

Supplemental Content

Support Center